NASDAQ:RXRX

Recursion Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy RXRX

*Your capital is at risk

$3.52

+0.180 (+5.39%)

At Close: Jun 26, 2026

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

06:56pm, Tuesday, 11'th Feb 2025

Recursion Pharmaceuticals (RXRX) closed at $7.66 in the latest trading session, marking a +0.13% move from the prior day.

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

05:24pm, Wednesday, 05'th Feb 2025

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported 12 month data from the Phase 2 study (SYCAMORE) of REC-994, the first industry sponsored Phase 2 trial completed in

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note

06:56pm, Monday, 03'rd Feb 2025

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $7.25, representing a +0.14% change from its previous close.

Cathie Wood's Top Biotech Plays for February

07:40pm, Sunday, 02'nd Feb 2025

Don't look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive technology funds posting high double-digit percentage returns.

3 Monster Stocks to Hold for the Next 10 Years

05:45am, Saturday, 01'st Feb 2025

Are you looking for high-odds, high-growth prospects to buy and hold for the next decade? That's a tall order to be sure.

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

10:46am, Thursday, 23'rd Jan 2025

Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

04:29am, Tuesday, 21'st Jan 2025

Investors looking for stocks that could make dramatic moves in a short, defined time frame will want to turn their attention toward two innovative drugmakers. A couple of stocks in the volatile biopha

Is Recursion Pharmaceuticals Stock a Buy?

05:47am, Friday, 17'th Jan 2025

Everything touching artificial intelligence (AI) is hot right now, so it's no surprise that the biotech Recursion Pharmaceuticals (RXRX -0.31%) could be positioned to ride the ongoing wave of hype to

Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

06:55pm, Wednesday, 15'th Jan 2025

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $6.42, marking a +1.58% move from the previous day.

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

11:01am, Friday, 10'th Jan 2025

The mean of analysts' price targets for Recursion Pharmaceuticals (RXRX) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

09:15am, Tuesday, 07'th Jan 2025

Salt Lake City, UT, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today that the UK M

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by